Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Homatropine
Drug ID BADD_D01075
Description Homatropine is an anticholinergic drug that acts as an antagonist at muscarinic acetylcholine receptors. It is present in antitussives, under the trade name Hycodan, in combination with hydrocodone (dihydrocodeinone) bitartrate indicated for the symptomatic relief of cough as oral tablets or solutions. Homatropine is included in subtherapeutic amounts as homatropine methylbromide to discourage deliberate overdosage. Homatropine hydrobromide has been administered as ophthalmic solutions as a cycloplegic to temporarily paralyze accomodation, and to induce mydriasis (the dilation of the pupil); however such therapeutic use has not been approved by the FDA to be safe and effective.
Indications and Usage
Marketing Status Not Available
ATC Code S01FA05
DrugBank ID DB11181
KEGG ID C07814
MeSH ID C100236
PubChem ID 688024
TTD Drug ID Not Available
NDC Product Code Not Available
Synonyms homatropine | homatropine, (3(S)-endo)-isomer | homatropine, exo-(+-)-isomer | I - Homatrine | Isopto Homatropine | Minims-Homatropin | AK-Homatropine | Homatropin - POS | homatropine hydrobromide, (endo-(+-)-isomer) | homatropine hydrochloride, (endo-(+-)-isomer) | homatropine sulfate (1:1), (3(R)-endo)-isomer | homatropine sulfate (1:1), (3(S)-endo)-isomer | homatropine sulfate (2:1), endo-isomer | Minims-Homatropine Hydrobromide
Chemical Information
Molecular Formula C16H21NO3
CAS Registry Number 87-00-3
SMILES CN1C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Agitation19.06.02.001; 17.02.05.012--
Anhidrosis23.02.03.001--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Bladder dilatation20.03.01.007--Not Available
Body temperature increased13.15.01.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis11.01.06.012; 06.04.01.002--
Dermatitis23.03.04.002--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Drug effect prolonged08.06.01.012--Not Available
Eczema23.03.04.006--
Endophthalmitis11.01.06.003; 06.04.05.009--
Eye discharge06.04.05.001--Not Available
Eye disorder06.08.03.001--Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Feeling abnormal08.01.09.014--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Glaucoma06.03.01.002--
Hallucination19.10.02.002--
Heart rate irregular13.14.04.003--Not Available
Hyperkinesia17.01.02.008--Not Available
Hyperpyrexia08.05.02.002--Not Available
Hypotension24.06.03.002--
Incoherent19.10.03.006; 17.02.08.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Nervous system disorder17.02.10.001--Not Available
Ocular hyperaemia06.04.05.004--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages